TB-500

Goldstein et al. (2012) — Canonical mechanism and clinical applications review

Goldstein A.L., Hannappel E., Sosne G., Kleinman H.K., 2012, Expert Opinion on Biological Therapy 🐀 Animal + early human (review)

This review by the core Tβ4 team — Goldstein, Hannappel, Sosne, and Kleinman — synthesises decades of work on Tβ4's fundamental biology and its path toward clinical use. It covers actin sequestration, cell migration, anti-inflammatory signalling, angiogenesis, and the ILK–Akt survival pathway, then surveys early clinical evidence across wound healing, cardiac repair, and ophthalmic indications. The paper is explicit that clinical work involves topical formulations of full Tβ4, not injected fragments.

Limitations: Narrative review by the primary researchers; no new primary data. Authors have direct institutional interests in Tβ4 commercialisation.

PubMed 22074294

Bock-Marquette et al. (2004) — Cardiac repair via ILK activation in mice

Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D., 2004, Nature 🐀 Animal (mice)

Bock-Marquette and colleagues showed that Tβ4 activates integrin-linked kinase (ILK) and promotes migration and survival in embryonic and adult cardiomyocytes. Mice subjected to coronary ligation and then treated with Tβ4 showed significantly reduced infarct size and improved cardiac function. The mechanism involved ILK activation, downstream Akt phosphorylation, and suppressed cardiomyocyte apoptosis — the first clear molecular explanation for Tβ4's cardiac protective effects in a living mammal and a landmark in the field.

Limitations: Mouse model; small-animal cardiac results have historically translated poorly to humans. No cardiac human trials with injected Tβ4 or TB-500 have been published.

PubMed 15565145

Sosne et al. (2001) — Corneal wound healing and anti-inflammatory effects in vivo

Sosne G., Szabo I.L., Victorov I., Shekhter A.B., Kazlauskas A., Bhargava H.N., Siegner S.W., Gausas R., Goldstein A.L., Kublin C.L., 2001, Experimental Eye Research 🐀 Animal (mice) + topical formulation work

Sosne and colleagues tested topical Tβ4 in mouse corneal abrasion and alkali-burn models. Mice receiving Tβ4 eye drops showed accelerated re-epithelialisation at all timepoints, reduced leukocyte infiltration, and lower transcript levels for pro-inflammatory mediators including IL-1α, TNF-α, and MIP-2. The peptide acted simultaneously as a cell-migration promoter and an anti-inflammatory agent. This work established the preclinical foundation for the RegeneRx ophthalmic programme (RGN-259) and is one of the most-cited papers in the Tβ4 literature.

Limitations: Mouse corneal model, topical administration only. Corneal epithelium heals exceptionally well; findings may not predict effects in tendons, muscle, or with systemic injection.

PubMed 11311052

Philp et al. (2003) — Dermal wound repair in diabetic and aged mice

Philp D., St-Surin S., Cha H.J., Moon H.S., Kleinman H.K., Elkin M., 2003, FASEB Journal 🐀 Animal (mice)

Using full-thickness dermal wound models in genetically diabetic (db/db) and aged mice — two populations with clinically relevant impaired healing — Philp and colleagues showed that Tβ4 significantly accelerated wound closure and improved collagen deposition. Notably, a synthetic actin-binding fragment corresponding to the LKKTETQ sequence reproduced much of this effect, providing early preclinical evidence that a shorter peptide retaining this domain (the structural basis for TB-500) can recapitulate key wound-healing activities.

Limitations: Animal models only; db/db mouse physiology does not fully replicate human diabetic wound pathology. The LKKTETQ fragment tested is not identical to commercial TB-500 constructs, and human dose–response data do not exist.

Dry eye Phase II RCT (2015) — Randomised controlled trial of topical Tβ4

Sosne G. et al., 2015, Cornea 🧑 Human (Phase II RCT, topical)

This double-masked, placebo-controlled Phase II study randomised 72 patients with moderate-to-severe dry eye to 0.1% topical Tβ4 (RGN-259) or vehicle. Using a Controlled Adverse Environment chamber to standardise symptom provocation, the Tβ4 group showed statistically significant improvements in inferior corneal fluorescein staining and ocular discomfort scores. This is the highest-quality human evidence in the Tβ4 literature — and its purpose here is to mark exactly where the evidence stops: topical ophthalmic use in dry eye patients, not injected systemic use for any performance-related indication.

Limitations: n=72, single centre, topical only. Pharmacokinetics of an eye drop bear no relation to subcutaneous injection; findings cannot be extrapolated to injectable TB-500.

Goldstein (2011) — Animal studies overview: multifunctional tissue repair

Goldstein A.L., Kleinman H.K., 2011, Annals of the New York Academy of Sciences 🐀 Animal (multiple models, review)

This review surveys preclinical Tβ4 findings across skin, cardiac, corneal, and neurological injury models, covering hair follicle stem cell activation, cardiac progenitor mobilisation, vessel sprouting, and neuroprotection after spinal cord injury in rodents. It positions Tβ4 as one of the most pleiotropic endogenous repair signals identified to date. For evaluating TB-500 claims, the paper's value is to confirm that the biological plausibility of actin-binding peptides in tissue repair is genuine — grounded in decades of independent work. The leap from biologically plausible to proven safe and effective via injection in humans remains entirely undemonstrated.

Limitations: Review with no new primary data; authored by the primary research group. The breadth of positive animal findings has not produced a single approved human indication for injected Tβ4.